OncoEthix In-Licenses anticancer compoundSBA News Network, 27.06.2012
Dr Esteban Cvitkovic, Chief Scientific Officer of OncoEthix, noted that "the studies that we performed have confirmed that OTX015 is active across a wide range of hematologic malignancies. I look forward to exploring the compound's potential in the clinic." Dr Kay Noel, Chief Operating Officer who led the licensing effort with Bertrand Damour, Chief Executive Officer, said: "We are excited about the opportunity to lead the exploration of one of the most promising new cancer targets." OncoEthix is a privately held biotechnology company based in Lausanne that plans to develop a small portfolio of oncology drug candidates, ensuring a proper foundation for commercial success. The company's lead product, OTX008, a synthetic small molecule targeted to galectin-1, entered Phase 1 clinical trial in the first quarter of 2012. OncoEthix was incorporated in 2007 and completed a Series A financing round led by Index Ventures and Endeavour Vision in August 2009.